NRG1 and pancreatic adenocarcinoma: The anti-HER2xHER3 bispecific antibody zenocutuzumab was granted breakthrough designation by the FDA in advanced NRG1-fusion positive pancreatic cancer, based on the results of the ongoing phase 1/2 eNRGy trial (NCT02912949) in 2021.175,176 In 2024, zenocutuzumab-zbco received accelerated approval for previously treated, NRG1 gene fusion-positive pancreatic adenocarcinoma and NSCLC.177 This approval was based on encouraging ORR in pancreatic adenocarcinoma (40%, n = 30) and NSCLC (33%, n = 64).